Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review
Hajar Alammar, Rayan Nassani, Mana Alshehri, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 464-464
Open Access | Times Cited: 11

Showing 11 citing articles:

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 599
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Qingfang Li, Zhihui Li, Ting Luo, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 105
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
Devendra Kumar, Ranjana Kanchan, Nagendra K. Chaturvedi
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data
Ashley N. Spirrison, Deborah A. Lannigan
Expert Opinion on Therapeutic Targets (2024), pp. 1-13
Open Access | Times Cited: 2
Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies
Hasan Slika, Aanya Shahani, Riddhpreet Kaur Wahi, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2249-2249
Open Access | Times Cited: 1
Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma
Veronica Marabitti, Manuela Giansanti, Francesca De Mitri, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 6
Three generations of mTOR kinase inhibitors in the activation of the apoptosis process in melanoma cells
Dorota Ciołczyk-Wierzbicka, Agnieszka Krawczyk, Marta Zarzycka, et al.
Journal of Cell Communication and Signaling (2023) Vol. 17, Iss. 3, pp. 975-989
Open Access | Times Cited: 3
Unraveling the secrets of Medulloblastoma: a comprehensive review of molecular pathways associated with pathogenesis, therapeutic resistance and potential treatment strategies
Sarmad Habib Khan, Bisma Khalil, Hina Kausar, et al.
Journal of Health and Rehabilitation Research (2024) Vol. 4, Iss. 1, pp. 127-132
Open Access
Personalized treatment options of refractory and relapsed medulloblastoma in children: literature review
Yu. V. Dinikina, Olga Zheludkova, М. Б. Белогурова, et al.
Journal of Modern Oncology (2024) Vol. 25, Iss. 4, pp. 454-465
Open Access
Expression Levels of PF4, ALOX12, ITGA2B, F131A in Pregnant COVID-19 Survivors
Mai Shaker, Asia E Abdelghany, Nesma M. Elaraby
Biochemical Genetics (2024)
Closed Access
Effectiveness of metronomic chemotherapy in a child with medulloblastoma: A case report
Elena Lygina, D. A. Morgacheva, Avinash Khadela, et al.
Oncology Letters (2023) Vol. 25, Iss. 5
Open Access
Page 1

Scroll to top